Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia - Wikidata - wikimedia - TriplyDB

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

http://www.wikidata.org/entity/Q26785828

about

Bispecific antibodies and their applications Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor CCR9 in cancer: oncogenic role and therapeutic targeting Second-generation inhibitors of Bruton tyrosine kinase Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Immunotherapy in hematologic malignancies: past, present, and future.Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.New development in CAR-T cell therapy.Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab.The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.Recent advances of bispecific antibodies in solid tumors.Syk inhibitors in clinical development for hematological malignancies.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Cancer immunotherapy beyond immune checkpoint inhibitors.Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.Bispecific antibodies: design, therapy, perspectives.Bone marrow stromal cells enhance the survival of chronic lymphocytic leukemia cells by regulating HES-1 gene expression and H3K27me3 demethylation.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Immuno-Oncology: Emerging Targets and Combination Therapies

P2860

Q26774024-ABE07EC7-2224-4BC6-8483-F3F65D1FED7F Q27300701-CCB9C906-8CA7-420D-8DE7-388876134063 Q28066316-4E70AC5F-E6B7-41DF-848D-230B73D91096 Q28066712-2D3E173F-B36C-48F8-96D0-23B85527B3E0 Q28076118-398D477B-8E2F-4B79-9194-B7CC59394E28 Q30275229-841643E9-A60E-4A3F-9880-AC044DF8BD4B Q33593865-1E805A05-918A-410E-A3DA-0E183C81E309 Q36591877-C2D1D164-939B-4C3E-98D2-1290205B7245 Q37012569-A6CDF7E1-3A2F-4D06-8B85-3387F701D1E6 Q37119773-BC5FC6FE-F35E-4557-9AE7-050238D3D843 Q37129564-2E5E93C1-1EA9-4E0B-8DFA-0D8A23044D14 Q37615772-75D67B86-6DA7-46E9-A56A-B61C72B72FFC Q37619710-95FFB10E-FE5B-4489-9629-FF8549D4C9AA Q37658246-A232E85E-0465-4874-91E2-9D25BEAB0913 Q37708939-6F41A719-4260-415C-A417-CBD221C28F24 Q38558611-42771C9C-CEA8-4C0C-AA96-292419F86551 Q38640263-F8168644-E51B-4E22-A38D-6D0165A27173 Q38640917-688586EC-AE9B-4D38-9E6B-1744341313A9 Q38759986-7F023B25-9529-451D-A92C-8AF0A47E670A Q38989496-1F1AABD9-E6E2-4159-8D25-02191534F42A Q41048538-87CA0F11-C5DD-4947-8641-B1426EA906AB Q41149154-7024FFE0-38A1-411A-ADA5-ADFB31F819F1 Q41264328-DA0950AC-E63A-42EA-8A92-0505DB7FA7A9 Q41696278-FF2695DC-4AFF-4D93-BC94-CB847C90AE3E Q42011012-E19F8017-5C44-4838-92C4-21F473CA4D8D Q47103332-A220C4F3-1269-4786-9625-1FAA69EE60C5 Q47554248-DEAF2264-CD76-47E3-A951-C10CBB4A419E Q48187016-09E71C7A-487C-4735-8453-A5F3A5B50CEA Q48226662-243ECF11-ADB3-41A4-A3FA-0CDE65061CC8 Q49195146-8515FA54-E322-4D14-9373-99BF8206026F Q49592081-5E2534EC-6B42-48FB-BBC5-2B162742C823 Q49878390-B8D1751B-049D-42BE-A35C-3E886B120089 Q55216327-79241766-936B-422F-99F3-79EF54798C1A Q56889817-9CD02982-516B-4AF1-A912-E20ECBEACE7A

P2860

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

http://www.wikidata.org/entity/Q26785828

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@ast

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@en

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@nl

type

label

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@ast

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@en

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@nl

prefLabel

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@ast

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@en

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@nl

P1433

Q26785828-41BD721D-1E99-4179-8D98-D098E61F817D

P1476

Q26785828-AD62500B-BAAD-4F3B-8EB5-662488FDC000

P2093

Q26785828-2417F14A-0618-47AC-8281-E48326016355

Q26785828-3298A2F7-692D-48E1-B051-943E9D79635E

Q26785828-4724A3CD-28D1-4442-8543-F4286680F0C6

Q26785828-C47BC5FA-1DD8-4CB1-A87E-B5C3D4F3E95C

P275

Q26785828-769C9F99-606A-4A75-BFE6-2E8385B417AB

P2860

Q26785828-02D82797-6F70-451F-BE4C-D8DCE395671A

Q26785828-0303A57C-D3AE-48D2-93E9-BFE73DCDC9EB

Q26785828-05AE13A3-7239-4064-93A4-0BF397879382

Q26785828-08AF3B07-F238-48D1-AE2D-BCBD14F8E5AA

Q26785828-0A1BF0BC-993B-492F-BC66-C4EA5F48985F

Q26785828-0BAF1EE1-7153-4CAA-BE9F-7D8C2F315CBC

Q26785828-132BE079-6520-45E8-92F0-C093F912E9F5

Q26785828-1DEE2854-8942-4B5F-8E06-69F4841BB5A4

Q26785828-1FBE7315-B2E8-4B83-AA8E-0FD9AF0BCE0C

Q26785828-22AAC3C0-B056-4E5E-93F9-2EBB6F8B3248

P2888

Q26785828-3BED1D2E-BCCE-491B-ACEA-25D515947659

P304

Q26785828-56E70184-3643-423C-8961-FE7189B5026B

P31

Q26785828-03B0A9A7-BE20-4445-BC62-DF9377F93940

Q26785828-A7C194C3-2BB0-4B21-A38F-3F851ACED1CC

P3181

Q26785828-4E67DB90-9828-4C1D-9CE1-FB87684CB568

P356

Q26785828-4E888B6C-6BF5-4A8A-A9AE-0FC133BD57C6

P407

Q26785828-A2E369B3-75DC-44A6-9342-2E4321DE9F45

P433

Q26785828-47EBF435-9C78-4E2C-A8B7-69A9EB769853

P478

Q26785828-FE16807C-12F4-485B-A67D-91B76E90E537

P5008

Q26785828-A5E45B28-DEAB-4F10-B19B-316AA2FB6DFB

P577

Q26785828-6B1F4C13-FE89-4303-B880-8F25F0134229

P5875

Q26785828-349C5AC6-14CB-4B3E-808C-278249A7CB5A

P6179

Q26785828-7A2FFA2D-7344-4EBB-82CC-8E2A46F5F38A

P698

Q26785828-85201C51-295C-4962-9C80-FF3957B8138E

P921

Q26785828-026690A6-3BC6-4BA4-AEE2-A4E53CEEDC0A

Q26785828-09C7A7E5-B383-4F0F-91F7-D12FAB154437

Q26785828-C7B98F59-EB0E-4314-9280-068F9D55C67B

Q26785828-CF424426-FCC9-4962-9D8B-7B610EF4017A

Q26785828-E6D8D7F9-1B83-4397-BAC6-D3FD6102831C

P932

Q26785828-8F2ECF7F-44DC-4BB2-9DE1-6D13726C650E

P3181

P356

S13045-015-0195-4

P1433

Journal of Hematology & Oncology

P1476

Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia

@en

P2093

Delong Liu

http://www.w3.org/2001/XMLSchema#string

Jiaping Fu

http://www.w3.org/2001/XMLSchema#string

Jingjing Wu

http://www.w3.org/2001/XMLSchema#string

Mingzhi Zhang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

B-Raf and the inhibitors: from bench to bedside

"Diabodies": small bivalent and bispecific antibody fragments

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Novel agents and biomarkers for acute lymphoid leukemia

Immune Checkpoint Blockade in Cancer Therapy

Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies

MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells

New antibody approaches to lymphoma therapy

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

P2888

s13045-015-0195-4

P304

104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3698345

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13045-015-0195-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281466806

http://www.w3.org/2001/XMLSchema#string

P6179

1047120600

http://www.w3.org/2001/XMLSchema#string

P698

26337639

http://www.w3.org/2001/XMLSchema#string

P921

precursor lymphoblastic lymphoma/leukemia

P932

4558758

http://www.w3.org/2001/XMLSchema#string